Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 3
2013 53
2014 109
2015 164
2016 174
2017 152
2018 181
2019 218
2020 252
2021 209
2022 549
2023 578
2024 180

Text availability

Article attribute

Article type

Publication date

Search Results

2,489 results

Results by year

Filters applied: . Clear all
Page 1
Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics.
Bhatia S, Kramer M, Russo S, Naik P, Arun G, Brophy K, Andrews P, Fan C, Perou CM, Preall J, Ha T, Plenker D, Tuveson DA, Rishi A, Wilkinson JE, McCombie WR, Kostroff K, Spector DL. Bhatia S, et al. Cancer Res. 2022 Apr 1;82(7):1174-1192. doi: 10.1158/0008-5472.CAN-21-2807. Cancer Res. 2022. PMID: 35180770 Free PMC article.
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche.
Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, Zhao X, Estivill G, Adam I, Sanchez X, McCarthy S, Schaller J, Khan Z, Ruzo A, Pastorello R, Richardson ET, Dillon D, Montero-Llopis P, Barroso-Sousa R, Forman J, Shukla SA, Tolaney SM, Mittendorf EA, von Andrian UH, Wucherpfennig KW, Hemberg M, Agudo J. Baldominos P, et al. Cell. 2022 May 12;185(10):1694-1708.e19. doi: 10.1016/j.cell.2022.03.033. Epub 2022 Apr 20. Cell. 2022. PMID: 35447074 Free article.
Extracellular vesicles from triple negative breast cancer promote pro-inflammatory macrophages associated with better clinical outcome.
Tkach M, Thalmensi J, Timperi E, Gueguen P, Névo N, Grisard E, Sirven P, Cocozza F, Gouronnec A, Martin-Jaular L, Jouve M, Delisle F, Manel N, Rookhuizen DC, Guerin CL, Soumelis V, Romano E, Segura E, Théry C. Tkach M, et al. Proc Natl Acad Sci U S A. 2022 Apr 26;119(17):e2107394119. doi: 10.1073/pnas.2107394119. Epub 2022 Apr 19. Proc Natl Acad Sci U S A. 2022. PMID: 35439048 Free PMC article.
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, Zahm DM, Hanusch C, Thomalla J, Jackisch C, Staib P, Link T, Rhiem K, Solbach C, Fasching PA, Nekljudova V, Denkert C, Untch M; GBG and AGO-B. Loibl S, et al. Ann Oncol. 2022 Nov;33(11):1149-1158. doi: 10.1016/j.annonc.2022.07.1940. Epub 2022 Aug 9. Ann Oncol. 2022. PMID: 35961599 Free article. Clinical Trial.
2,489 results